VRNA
Income statement / Annual
Last year (2023), Verona Pharma plc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Verona Pharma plc's net income was -$54.37 M.
See Verona Pharma plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$458,000.00
|
$40.00 M
|
$0.00
|
$2,351.00
|
$2,783.00
|
$1.84 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$679,624.00 |
$346,000.00 |
$0.00 |
$627,846.00 |
$512,111.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$679,624.00 |
$112,000.00 |
$40.00 M |
-$627,846.00 |
-$509,760.00 |
$2,783.00 |
$1.84 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0.24 |
1 |
0 |
-216.83 |
1 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$17.28 M
|
$49.28 M
|
$79.41 M
|
$44.51 M
|
$43.89 M
|
$24.48 M
|
$32.05 M
|
$5.58 M
|
$10.76 M
|
$4.10 M
|
| General & Administrative
Expenses |
$0.00
|
$7.20 M
|
$11.66 M
|
$29.77 M
|
$8.99 M
|
$7.99 M
|
$8.10 M
|
$2.89 M
|
$2.51 M
|
$1.80 M
|
| Selling & Marketing
Expenses |
$0.00
|
$19.38 M
|
$22.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.87 M
|
$26.58 M
|
$33.91 M
|
$29.77 M
|
$8.99 M
|
$7.99 M
|
$8.10 M
|
$2.89 M
|
$2.51 M
|
$1.80 M
|
| Other Expenses |
$0.00 |
-$9.63 M |
-$15.63 M |
-$8.27 M |
$527,088.00 |
$16,495.00 |
$23,000.00 |
$1.07 M |
$1.17 M |
$0.00 |
| Operating Expenses |
$67.15 M |
$66.23 M |
$97.68 M |
$66.01 M |
$53.41 M |
$32.48 M |
$40.16 M |
$8.49 M |
$13.29 M |
$5.90 M |
| Cost And Expenses |
$67.83 M |
$66.57 M |
$97.68 M |
$66.01 M |
$53.41 M |
$32.48 M |
$40.16 M |
$8.49 M |
$13.29 M |
$5.90 M |
| Interest Income |
$12.81 M |
$2.82 M |
$14,000.00 |
$121,000.00 |
$988,619.00 |
$1.09 M |
$466,235.00 |
$106,776.00 |
$66,358.00 |
$46,659.00 |
| Interest Expense |
$2.06 M |
$521,000.00 |
$340,000.00 |
$35,000.00 |
$221,587.00 |
$0.00 |
$98,652.00 |
$104,516.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$679,624.00
|
$636,000.00
|
$629,000.00
|
$627,846.00
|
$512,111.00
|
$124,352.00
|
$166,222.00
|
$76,029.00
|
$78,691.00
|
$82,433.00
|
| EBITDA |
-$52.47 M
|
-$67.29 M
|
-$42.19 M
|
-$47.81 M
|
-$32.17 M
|
-$25.50 M
|
-$29.64 M
|
-$6.96 M
|
-$8.92 M
|
-$3.74 M
|
| EBITDA Ratio |
0 |
-136.81 |
-1.43 |
0 |
-22018.22 |
-11235.05 |
-21.46 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-144.36
|
-1.83
|
0
|
-22912.22
|
-11668.2
|
-21.84
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$12.62 M
|
$7.30 M
|
-$1.37 M
|
$6.78 M
|
$8.99 M
|
$1.46 M
|
$4.55 M
|
$1.05 M
|
-$28,000.00
|
$29,978.00
|
| Income Before Tax |
-$55.21 M |
-$68.45 M |
-$55.59 M |
-$65.00 M |
-$51.41 M |
-$30.62 M |
-$34.06 M |
-$7.37 M |
-$13.22 M |
-$5.86 M |
| Income Before Tax Ratio
|
0
|
-149.45
|
-1.39
|
0
|
-21865.41
|
-11003.42
|
-18.5
|
0
|
0
|
0
|
| Income Tax Expense |
-$474,000.00 |
$253,000.00 |
-$18,000.00 |
$146,000.00 |
-$9.53 M |
-$5.37 M |
-$6.36 M |
-$1.18 M |
-$2.24 M |
-$1.56 M |
| Net Income |
-$54.37 M |
-$68.70 M |
-$55.57 M |
-$65.15 M |
-$41.88 M |
-$25.25 M |
-$27.70 M |
-$6.19 M |
-$10.99 M |
-$4.29 M |
| Net Income Ratio |
0 |
-150 |
-1.39 |
0 |
-17813.67 |
-9073.85 |
-15.05 |
0 |
0 |
0 |
| EPS |
-0.54 |
-1.04 |
-0.94 |
-1.98 |
-3.18 |
-0.19 |
-0.25 |
-0.003 |
-0.0087 |
-0.004 |
| EPS Diluted |
-0.54 |
-1.04 |
-0.94 |
-1.98 |
-3.18 |
-0.19 |
-0.25 |
-0.003 |
-0.0087 |
-0.004 |
| Weighted Average Shares
Out |
$79.27 M
|
$66.13 M
|
$59.15 M
|
$32.87 M
|
$13.17 M
|
$131.39 M
|
$109.69 M
|
$2.09 B
|
$1.26 B
|
$1.08 B
|
| Weighted Average Shares
Out Diluted |
$79.27 M
|
$66.13 M
|
$59.15 M
|
$32.87 M
|
$13.17 M
|
$131.39 M
|
$109.69 M
|
$2.09 B
|
$1.26 B
|
$1.08 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
